RU2350345C1 - Agent increasing visual acuity - Google Patents
Agent increasing visual acuity Download PDFInfo
- Publication number
- RU2350345C1 RU2350345C1 RU2007120697/15A RU2007120697A RU2350345C1 RU 2350345 C1 RU2350345 C1 RU 2350345C1 RU 2007120697/15 A RU2007120697/15 A RU 2007120697/15A RU 2007120697 A RU2007120697 A RU 2007120697A RU 2350345 C1 RU2350345 C1 RU 2350345C1
- Authority
- RU
- Russia
- Prior art keywords
- visual acuity
- amaranth
- agent
- increasing visual
- agent increasing
- Prior art date
Links
- 230000004304 visual acuity Effects 0.000 title claims abstract description 11
- 240000001592 Amaranthus caudatus Species 0.000 claims abstract description 11
- 235000009328 Amaranthus caudatus Nutrition 0.000 claims abstract description 11
- 235000012735 amaranth Nutrition 0.000 claims abstract description 11
- 239000004178 amaranth Substances 0.000 claims abstract description 11
- 239000006286 aqueous extract Substances 0.000 claims description 3
- 239000003814 drug Substances 0.000 abstract description 7
- 239000000284 extract Substances 0.000 abstract description 7
- 230000000694 effects Effects 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 230000000630 rising effect Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 208000002177 Cataract Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 208000009857 Microaneurysm Diseases 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000000842 betacyanins Nutrition 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- 229940055416 blueberry extract Drugs 0.000 description 1
- 235000019216 blueberry extract Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- SZGZILRQIYNODJ-UHFFFAOYSA-L disodium;7,12-dihydroquinoxalino[3,2-b]phenazine-2,9-disulfonate Chemical compound [Na+].[Na+].[O-]S(=O)(=O)C1=CC=C2N=C(C=C3C(NC4=CC=C(C=C4N3)S(=O)(=O)[O-])=C3)C3=NC2=C1 SZGZILRQIYNODJ-UHFFFAOYSA-L 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 229930005346 hydroxycinnamic acid Natural products 0.000 description 1
- -1 hydroxycinnamic acid Chemical class 0.000 description 1
- 235000010359 hydroxycinnamic acids Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229940023490 ophthalmic product Drugs 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- NGSWKAQJJWESNS-ZZXKWVIFSA-N trans-4-coumaric acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C=C1 NGSWKAQJJWESNS-ZZXKWVIFSA-N 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Изобретение относится к фармакологии, а именно к биологически активным препаратам, обладающим способностью повышать остроту зрения, и может найти применение в биологии и медицине при разработке новых лекарственных средств для лечения глазных болезней, в том числе катаракты.The invention relates to pharmacology, namely to biologically active drugs with the ability to increase visual acuity, and can find application in biology and medicine in the development of new drugs for the treatment of eye diseases, including cataracts.
Известны различные фармакологические средства, повышающие остроту зрения и используемые для лечения катаракты, полученные путем химического синтеза, например, квинакс /Инструкция по медицинскому применению препарата/. Однако синтетические лекарственные соединения имеют много побочных эффектов и узконаправленное действие. Предпочтительными являются средства, содержащие натуральные вещества растительного происхождения, например чернику, используемую и в виде экстракта (http\\www.rlsnet.ru\tn_chernikiekstrakt.html). Экстракт черники используют в виде капсул. Прием этого препарата улучшает состояние глаз, повышает остроту зрения.There are various pharmacological agents that increase visual acuity and are used to treat cataracts obtained by chemical synthesis, for example, quinax / Instructions for medical use of the drug /. However, synthetic drug compounds have many side effects and a highly targeted effect. Preferred are products containing natural substances of plant origin, for example blueberries, used in the form of an extract (http \\ www.rlsnet.ru \ tn_chernikiekstrakt.html). Blueberry extract is used in capsule form. Taking this drug improves the condition of the eyes, increases visual acuity.
Среди растений, используемых в народной медицине и в качестве пищи, выделяется амарант - растение, которое находит все более широкое применение благодаря высокому содержанию белка, масла, витаминов и других биологически активных веществ, а также биологической продуктивности. Его листья широко используются при приготовлении салатов, первых и вторых блюд, напитков (Кононков П.Ф., Гинс В.К., Гинс М.С. Амарант - перспективная культура XXI века. - М., РУДН, 1999, пат. РФ 2140432). Листья амаранта содержат антиоксиданты: бетацианины, флавоноиды, аскорбиновую кислоту, фенольные соединения, в том числе оксикоричную кислоту, набор незаменимых аминокислот, пектин, ионы калия и другие биологически активные вещества (Гинс В.К. Биологически активные вещества амаранта (амарантин: свойства, механизмы действия и практическое использование), М., РУДН, 2002, 183 с).Amaranth stands out among the plants used in folk medicine and as a food - a plant that is increasingly used due to its high content of protein, oil, vitamins and other biologically active substances, as well as biological productivity. Its leaves are widely used in the preparation of salads, first and second courses, drinks (Kononkov P.F., Gins V.K., Gins M.S. Amaranth - a promising culture of the XXI century. - M., RUDN, 1999, US Pat. 2140432). Amaranth leaves contain antioxidants: betacyanins, flavonoids, ascorbic acid, phenolic compounds, including hydroxycinnamic acid, a set of essential amino acids, pectin, potassium ions and other biologically active substances (Gins V.K. Biologically active substances of amaranth (amarantine: properties, mechanisms actions and practical use), M., RUDN University, 2002, 183 c).
Задачей изобретения является расширение арсенала глазных средств, повышающих остроту зрения и уменьшающих катаракту без побочных эффектов.The objective of the invention is to expand the arsenal of ophthalmic drugs that increase visual acuity and reduce cataracts without side effects.
Поставленная задача решается предлагаемым средством для повышения остроты зрения, представляющим собой водный экстракт из листьев амаранта.The problem is solved by the proposed means for increasing visual acuity, which is an aqueous extract from amaranth leaves.
Водный экстракт из листьев амаранта готовят из свежих или сухих измельченных листьев амаранта, заливают навеску листьев водой при 40-60°С, настаивают в течение 1-3 ч при соотношении: листья (сухой вес)-вода 1:10. Полученный экстракт фильтруют и используют в виде глазных капель по 2 капли 2-3 раза в день в течение месяца, перерыв 10 дней, и затем процедуру повторяют. Оставшийся экстракт пьют по 100 г утром и вечером.An aqueous extract from amaranth leaves is prepared from fresh or dry shredded amaranth leaves, a weighed portion of leaves is poured with water at 40-60 ° C, insisted for 1-3 hours at a ratio of: leaves (dry weight) -water 1:10. The resulting extract is filtered and used in the form of eye drops, 2 drops 2-3 times a day for a month, a break of 10 days, and then the procedure is repeated. The remaining extract is drunk 100 g in the morning and evening.
При этом об эффективности действия препарата судили по объективным показателям зрения, полученным с использованием офтальмологического оборудования:In this case, the effectiveness of the drug was judged by objective indicators of vision obtained using ophthalmic equipment:
1) острота зрения,1) visual acuity
2) степень интенсивности помутнения в хрусталике,2) the degree of intensity of opacification in the lens,
3) состояние сосудов сетчатой оболочки глаза.3) the state of the vessels of the retina of the eye.
Изобретение иллюстрируется следующими примерами.The invention is illustrated by the following examples.
Пример 1. больной К., 78 лет, диагноз - начальная катаракта обоих глаз. 01.2006 г. VIS od = 0,8 с кор. 0,9, os = 0,4 с кор. 0,8.Example 1. Patient K., 78 years old, diagnosed with initial cataract of both eyes. 01.2006, VIS od = 0.8 s cor. 0.9, os = 0.4 s 0.8.
После приема экстракта амаранта внутрь и закапывания в глазаAfter ingestion of amaranth extract and instillation into the eyes
01.1007 г. Vis обоих глаз = 1,0.01.1007, Vis of both eyes = 1.0.
Пример 2. больной Т., 65 лет, диагноз - начальная возрастная катаракта обоих глаз.Example 2. Patient T., 65 years old, diagnosed with an initial age-related cataract of both eyes.
01.2006 г. Vis od = 0,8, os = 0,8.01.2006, Vis od = 0.8, os = 0.8.
Прием экстракта амаранта только внутрьAmaranth extract only inside
01.2007 г. Vis od = 1,0, os = 1,0.2007-01-01 Vis od = 1.0, os = 1.0.
Пример 3. больная М., 53 года, диагноз - сахарный диабет, диабетическая ретинопатия.Example 3. Patient M., 53 years old, diagnosed with diabetes mellitus, diabetic retinopathy.
10.2005 г. Vis od = 0,8, os = 0,8.10.2005 Vis od = 0.8, os = 0.8.
На глазном дне неравномерное сужение сосудов, микроаневризмы.On the fundus uneven narrowing of blood vessels, microaneurysms.
После приема экстракта амаранта внутрь и закапывания в глаза в течение двух месяцев с 10-тидневным перерывом Vis od = 1,0, os = 1,0. Состояние сосудов глазного дна улучшилось.After taking the amaranth extract by mouth and instillation into the eyes for two months with a 10-day break, Vis od = 1.0, os = 1.0. The condition of the fundus vessels has improved.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2007120697/15A RU2350345C1 (en) | 2007-06-04 | 2007-06-04 | Agent increasing visual acuity |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2007120697/15A RU2350345C1 (en) | 2007-06-04 | 2007-06-04 | Agent increasing visual acuity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007120697A RU2007120697A (en) | 2008-12-10 |
| RU2350345C1 true RU2350345C1 (en) | 2009-03-27 |
Family
ID=40542683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007120697/15A RU2350345C1 (en) | 2007-06-04 | 2007-06-04 | Agent increasing visual acuity |
Country Status (1)
| Country | Link |
|---|---|
| RU (1) | RU2350345C1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2001135504A (en) * | 2001-12-29 | 2003-08-27 | Всероссийский научно-исследовательский институт селекции и семеноводства овощных культур РАСХН | Means for protecting plants from diseases with growth-promoting effect |
| RU2005105802A (en) * | 2005-03-02 | 2006-08-10 | Сергей Иванович Аладьев (RU) | MEANS FOR PREVENTING ATHEROSCLEROSIS, IMPROVE MEMORY AND VISUAL VISUALITY |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2214710C2 (en) * | 2001-12-29 | 2003-10-27 | Всероссийский научно-исследовательский институт селекции и семеноводства овощных культур РАСХН | Preparation of growth-stimulating action for protecting plants against diseases |
-
2007
- 2007-06-04 RU RU2007120697/15A patent/RU2350345C1/en not_active IP Right Cessation
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2001135504A (en) * | 2001-12-29 | 2003-08-27 | Всероссийский научно-исследовательский институт селекции и семеноводства овощных культур РАСХН | Means for protecting plants from diseases with growth-promoting effect |
| RU2005105802A (en) * | 2005-03-02 | 2006-08-10 | Сергей Иванович Аладьев (RU) | MEANS FOR PREVENTING ATHEROSCLEROSIS, IMPROVE MEMORY AND VISUAL VISUALITY |
Non-Patent Citations (1)
| Title |
|---|
| Аннотированный отчет о научно-исследовательской работе за 2006 год. Перечень данных [он лайн] 01.03.2007 [найдено 30.07.2008] - найдено из Интернет: URL:www.ksu.ru/uni/bin_files/1_24_06_!142.rtf. * |
Also Published As
| Publication number | Publication date |
|---|---|
| RU2007120697A (en) | 2008-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Noreen et al. | Terminalia arjuna gum/alginate in situ gel system with prolonged retention time for ophthalmic drug delivery | |
| US10406189B2 (en) | Methods and compositions for treating and preventing signs or symptoms of eye disease | |
| JPH05508183A (en) | Hyaluronic acid purification method and fractionation of pure hyaluronic acid for ophthalmology | |
| CN109862899A (en) | Compositions and methods for treating dry eye syndrome and other traumatic non-keratinized epithelial surfaces | |
| Weniger et al. | Review of side effects and toxicity of chloroquine | |
| JP2021505650A (en) | Ophthalmic drug preparations and their use | |
| CA3198402A1 (en) | Use of penehyclidine in treatment or prevention of vision-impairing eye diseases | |
| RU2356519C1 (en) | Method of antistress macular retina protection in cataract surgery in complicated diabetes patients | |
| JP2015519398A (en) | Therapeutic formulations and methods of treatment | |
| KR20140042008A (en) | A mosquito repellent composition containing citronella oil | |
| WO2017166888A1 (en) | Eyedrop and preparation method and application thereof | |
| CN107530380B (en) | Taiwanese Propolis Extract for Eye Diseases | |
| RU2350345C1 (en) | Agent increasing visual acuity | |
| RU2071316C1 (en) | Eye drops for cataract treatment | |
| CN110025625A (en) | Luteolin -7-O- glucoside or luteolin -7-O- glucuronide are in the application for preparing eye injury drug | |
| Vale et al. | Drugs and the Eye: Sponsored by the British Optical Association | |
| RU2662364C2 (en) | Method for cataract treatment and eye drops for implementation thereof | |
| TW200918075A (en) | Compositions and methods for modulating endophthalmitis using fluoroquinolones | |
| EP3682867B1 (en) | Lutein-containing ophthalmic composition | |
| RU2223099C1 (en) | Eye drops for treating glaucoma | |
| EP2709643B1 (en) | Compositions comprising extracts or materials derived from palm oil vegetation liguor for inhibition of vision loss due to macular degeneration | |
| RU2221584C2 (en) | Preparation for ophthalmiatrics | |
| TWI766565B (en) | Compositions for treating ocular diseases and use thereof | |
| RU2830747C1 (en) | Use of penegyclidine for treating or preventing eye diseases impairing vision | |
| AU2020352751A1 (en) | Composition of a dietary supplement and/or a nutritional additive for food, a unitary dosage form of said composition, and their use for improvement of the quality of visual performance including contrast sensitivity in persons in need of such an improvement, including persons suffering from at least one eye disease, particularly vitreous floaters |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20090605 |